Bristol Myers Squibb (BMY) Stock
Diversified biopharmaceutical company with oncology and immunology medicines. Here's the price, business snapshot, and what's worth knowing about Bristol Myers Squibb in August 2026.
Bristol-Myers Squibb (BMY) is a large, diversified biopharmaceutical company with a market cap of about $90.7bn. Investors should know it combines an established portfolio of marketed medicines—particularly in oncology, haematology and immunology—with a deep pipeline and substantial R&D spending. Key revenue drivers include immuno‑oncology and speciality medicines, though some legacy products face generic competition as patents expire. The 2019 Celgene acquisition broadened product mix but increased leverage, making cash generation and debt management important considerations. Regulatory outcomes, trial results and competitive approvals can move the share price materially. BMY typically pays a dividend, which may appeal to income‑minded investors, but dividends and share values can fall. This summary is for educational purposes only and not personalised advice; always consider your risk tolerance and do further research or speak to a financial adviser before investing.
Why It’s Moving
Bristol Myers stays in the spotlight as mixed analyst calls and fading merger hopes weigh on sentiment.
- A fresh round of analyst commentary has kept attention on BMY, with Jefferies cutting the stock to hold while Argus moved the other way and upgraded it to buy, underscoring a split view on the company’s near-term setup.
- Bristol Myers’ second-quarter results and raised full-year guidance helped steady sentiment, but the stock is still trading against a backdrop of slower visibility into long-term growth beyond the current portfolio momentum.
- Recent merger speculation around AstraZeneca and Bristol Myers briefly lifted the shares, but Reuters later reported there were no active talks, removing a potential takeover premium and refocusing investors on fundamentals.
- The latest company-specific catalyst was the August 13 FDA accelerated approval of ZENBEXUS for multiple myeloma, which adds another product win but has not fully offset analyst concerns about downside risk.
Bristol Myers stays in the spotlight as mixed analyst calls and fading merger hopes weigh on sentiment.
- A fresh round of analyst commentary has kept attention on BMY, with Jefferies cutting the stock to hold while Argus moved the other way and upgraded it to buy, underscoring a split view on the company’s near-term setup.
- Bristol Myers’ second-quarter results and raised full-year guidance helped steady sentiment, but the stock is still trading against a backdrop of slower visibility into long-term growth beyond the current portfolio momentum.
- Recent merger speculation around AstraZeneca and Bristol Myers briefly lifted the shares, but Reuters later reported there were no active talks, removing a potential takeover premium and refocusing investors on fundamentals.
- The latest company-specific catalyst was the August 13 FDA accelerated approval of ZENBEXUS for multiple myeloma, which adds another product win but has not fully offset analyst concerns about downside risk.
Sixth Month Growth Performance
next-earnings-question
Bristol Myers Squibb’s next earnings date is expected to be October 29, 2026. The upcoming report will cover Q3 2026 results. This timing is consistent with the company’s historical late-October reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Bristol Myers Squibb's stock, with a target price slightly below its current price.
Financial Health
Bristol Myers Squibb is performing well with strong revenue and cash flow, indicating solid financial health.
Dividend
Bristol Myers Squibb's dividend yield of 2.94% offers a decent return for dividend-seeking investors. If you invested $1000 you would be paid $29.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Oncology-led revenue engine
BMY’s oncology and haematology drugs drive sales and headline growth, though trial outcomes and competition can cause swings in performance.
Pipeline and R&D programme
A substantial pipeline offers upside if trials succeed, but R&D failures and regulatory delays are common and can affect value.
Cash flow and balance
Established medicines and partnerships support cash flow, yet patent cliffs and post-acquisition debt make balance-sheet management important.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
